SK biopharmaceuticals Co., Ltd.
Develops and commercializes CNS and oncology therapies for global markets, focusing on the U.S.
326030 | KO
Overview
Corporate Details
- ISIN(s):
- KR7326030004
- LEI:
- Country:
- South Korea
- Address:
- 경기도 성남시 분당구 판교역로 221, 성남시
- Website:
- https://www.skbp.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
SK Biopharmaceuticals is a global, fully integrated pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies. The company's primary therapeutic area is central nervous system (CNS) disorders, with an expanding pipeline in oncology. Its business model encompasses the entire value chain, from research and development to direct commercialization in key global markets, particularly the United States. The company's flagship product is cenobamate (marketed as XCOPRI® in the U.S.), an anti-seizure medication that has demonstrated significant commercial growth. SK Biopharmaceuticals actively incorporates advanced technologies, including artificial intelligence, to accelerate its drug development process and address unmet medical needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-16 00:00 |
Regulatory News Service
투자판단관련주요경영사항
|
Korean | 12.8 KB | ||
| 2025-08-29 00:00 |
Regulatory News Service
대규모기업집단현황공시[분기별공시(개별회사용)]
|
Korean | 5.9 KB | ||
| 2025-08-14 00:00 |
Environmental & Social Information
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
|
Korean | 2.2 KB | ||
| 2025-08-14 00:00 |
Interim Report
반기보고서 (2025.06)
|
Korean | 4.6 MB | ||
| 2025-08-05 00:00 |
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
|
Korean | 15.7 KB | ||
| 2025-07-30 00:00 |
Report Publication Announcement
기업설명회(IR)개최(안내공시)
|
Korean | 6.0 KB | ||
| 2025-07-29 00:00 |
Regulatory News Service
단일판매ㆍ공급계약체결
|
Korean | 8.3 KB | ||
| 2025-06-24 00:00 |
Regulatory News Service
단일판매ㆍ공급계약체결
|
Korean | 8.3 KB | ||
| 2025-06-20 00:00 |
Environmental & Social Information
지속가능경영보고서등관련사항(자율공시)
|
Korean | 8.0 KB | ||
| 2025-06-18 00:00 |
M&A Activity
[기재정정]투자판단관련주요경영사항
|
Korean | 16.7 KB | ||
| 2025-06-02 00:00 |
Governance Information
기업지배구조보고서공시
|
Korean | 2.2 MB | ||
| 2025-05-30 00:00 |
Major Shareholding Notification
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
|
Korean | 148.0 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 2.2 MB | ||
| 2025-05-09 00:00 |
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
|
Korean | 15.7 KB | ||
| 2025-05-02 00:00 |
Report Publication Announcement
기업설명회(IR)개최(안내공시)
|
Korean | 6.0 KB |
Automate Your Workflow. Get a real-time feed of all SK biopharmaceuticals Co., Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for SK biopharmaceuticals Co., Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SK biopharmaceuticals Co., Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
